Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olympia: OC-01 in Neurotrophic Keratopathy
NCT04957758Phase 2Completed
- Sponsor
- Oyster Point Pharma
- Start
- Jun 2021
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of varenicline + nicotine patch in neurotrophic keratopathy (NK), sponsored by Oyster Point Pharma. Started Jun 2021; status: completed.
02
Drugs
varenicline + nicotine patch
03
Conditions
neurotrophic keratopathy (NK)
Beyond the preview
Go deeper on NCT04957758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04957758.